secwatch / observer
8-K filed March 2, 2026, 6:59 PM ET ticker GENB CIK 0002100782
other confidence high sentiment neutral materiality 0.25

Generate Biomedicines adopts amended charter and bylaws for public company governance

Generate Biomedicines, Inc.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 1.0

Generate Biomedicines, Inc.: Amended and restated bylaws to establish procedures for stockholder meetings, advance notice proposals, and conform to amended certificate (effective 2026-03-02).

Change
bylaw amendment
Effective
2026-03-02
Exact text from the filing
The Amended and Restated Bylaws amend and restate the Company’s bylaws in their entirety to, among other things: (i) establish procedures for the Company’s stockholders to take formal actions at meetings of stockholders; (ii) establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of the Company’s stockholders, including proposed nominations of persons for election to the Board; and (iii) conform to the amended provisions of the Amended and Restated Certificate.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 1.0

Generate Biomedicines, Inc.: Amended and restated certificate of incorporation to authorize 500M common shares, eliminate references to previous preferred series, authorize 10M undesignated preferred shares, and eliminate stockholder ability to act by written consent and call special meetings (effective 2026-03-02).

Change
charter amendment
Effective
2026-03-02
Exact text from the filing
The Amended and Restated Certificate amends and restates the Company’s existing amended and restated certificate of incorporation, as amended, in its entirety to, among other things: (i) authorize 500,000,000 shares of common stock; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; and (iv) eliminate the ability of the Company’s stockholders to take action by written consent in lieu of a meeting and call special meetings of stockholders.
View on SEC.gov

40 governance changes filed in the last 30 days. Browse all governance changes →

Generate Biomedicines, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-085780
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.